Portfolio Lab

Collegium Pharmaceutical, Inc

  • Stock
  • Ticker COLL
  • ISIN US19459J1043
  • Nasdaq

Health care · Pharmaceuticals · USA

$24.72 −1.94%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Collegium Pharmaceutical, Inc since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

COLLGlobal equities (VT)

$10,000 grew to $14,558. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −65.2% in 07/2019, measured from the peak in 03/2018. It took 59 months to get back to the old peak.

1-year return
−43.8%
5-year return p.a.
+5.6%
10-year return p.a.
+3.8%
Volatility p.a.
56.0%
Largest decline
−65.2%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue182178188209205194200216
Gross profit9897108129128117110125
Operating income3822356261313.729
EBITDA3923366362315.529
Net income132.412321714-1522
Earnings per share0.360.070.340.840.460.40-0.460.60
Balance sheet
Total assets1,6641,6311,5931,6071,6571,6522,1362,096
Liabilities1,4351,3971,3601,3331,3551,3401,8241,799
Equity229234232275302312312296
Cash7196117150231269129145
Cash flow
Operating cash flow85557278123577187
Capital expenditure-0.6-0.8-0.1-0.2-0.7-0.3-0.5-0.3
Free cash flow84557278122577186

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2025 at +61.6%, weakest 2018 at −7.0%. 5 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
5 Nov 2026$0.60
6 Aug 2026−$0.46
7 May 2026$0.40
26 Feb 2026$0.46
6 Nov 2025$0.84
7 Aug 2025$0.34
8 May 2025$0.07
27 Feb 2025$0.36
7 Nov 2024$0.27
8 Aug 2024$0.52
9 May 2024$0.71
22 Feb 2024$0.82

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€696m
Market cap in trading currency
$768m
Enterprise value
$623m
P/E
24.7
P/S
0.94
P/B
2.59
EV/Sales
0.76
EV/EBITDA
4.9
Earnings yield
4.0%
FCF yield
43.8%

Results (last four quarters)

Revenue
$815m
Gross profit
$481m
EBITDA
$128m
Net income
$38.2m
Earnings per share
$1.00
Revenue per share
$26.23
Revenue growth
+3.3%
Earnings growth
−30.9%

Profitability

Gross margin
59.0%
Operating margin
15.2%
Net margin
4.7%
Return on equity
13.4%
Return on assets
1.8%

Balance sheet and cash flow

Cash
$145m
Cash per share
$4.66
Financial debt
–
Debt/equity %
–
Current ratio
1.01
Book value per share
$9.54
Operating cash flow
$338m
Free cash flow
$336m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
31.1m
Volume
527,935
Avg. volume 3 months
775,267
Relative volume
0.7

Price and technicals

Price
$24.72
1 day
−1.9%
52-week high
$49.84
52-week low
$21.53
Distance to 52-week high
−50.4%
Distance to 52-week low
+14.8%
Distance to 50-day line
+6.3%
Distance to 200-day line
−21.8%
RSI (14)
54
Volatility 1M
34.8%

Performance

1 week
−2.4%
1 month
+5.2%
3 months
−9.6%
6 months
−27.4%
YTD
−46.6%
1 year
−44.4%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has COLL performed since 11/2016?

$10,000 grew to $14,558 by 20 Nov 2026, which is +3.8% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is COLL?

Volatility was 56.0% per year, measured on monthly returns. The largest decline from a peak was −65.2%, with the low in 07/2019.

How does COLL compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, COLL returned +3.8% at 56.0%. The correlation of monthly returns was 0.25; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Collegium Pharmaceutical, Inc (COLL): Return and risk